Aether Industries Ltd
Incorporated in 2013, Aether Industries Limited is a manufacturer of specialty chemicals. The company is sole Indian manufacturer for chemicals such as 4-(2-Methoxyethyl) Phenol (4MEP), and 3-Methoxy-2-Methylbenzoyl Chloride (MMBC), Thiophene-2-Ethanol (T2E), Ortho Tolyl Benzo Nitrile (OTBN), N-Octyl-D-Glucamine, Delta-Valerolactone, and Bifenthrin Alcohol.[1]
- Market Cap ₹ 10,894 Cr.
- Current Price ₹ 822
- High / Low ₹ 1,071 / 762
- Stock P/E 94.1
- Book Value ₹ 164
- Dividend Yield 0.00 %
- ROCE 7.49 %
- ROE 5.59 %
- Face Value ₹ 10.0
Pros
Cons
- Stock is trading at 5.01 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Chemicals Industry: Chemicals
Part of BSE 400 MidSmallCap Index Nifty Microcap 250 Nifty Total Market BSE 500 BSE SmallCap
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|
590 | 651 | 598 | 716 | |
422 | 465 | 466 | 544 | |
Operating Profit | 168 | 186 | 132 | 172 |
OPM % | 28% | 29% | 22% | 24% |
7 | 17 | 25 | 32 | |
Interest | 13 | 5 | 9 | 11 |
Depreciation | 15 | 23 | 40 | 42 |
Profit before tax | 146 | 174 | 110 | 150 |
Tax % | 26% | 25% | 25% | |
109 | 130 | 82 | 107 | |
EPS in Rs | 9.67 | 10.47 | 6.22 | 8.05 |
Dividend Payout % | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | 8% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | -8% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
1 Year: | -6% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
Last Year: | 6% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|
Equity Capital | 113 | 125 | 133 | 133 |
Reserves | 274 | 1,120 | 1,931 | 1,997 |
291 | 16 | 183 | 216 | |
92 | 120 | 154 | 219 | |
Total Liabilities | 770 | 1,380 | 2,401 | 2,565 |
257 | 646 | 853 | 881 | |
CWIP | 58 | 37 | 232 | 340 |
Investments | 17 | 1 | 0 | 0 |
438 | 695 | 1,315 | 1,343 | |
Total Assets | 770 | 1,380 | 2,401 | 2,565 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|
-5 | -7 | -16 | |
-151 | -348 | -424 | |
169 | 439 | 894 | |
Net Cash Flow | 12 | 84 | 453 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|
Debtor Days | 101 | 145 | 142 |
Inventory Days | 221 | 301 | 411 |
Days Payable | 95 | 99 | 124 |
Cash Conversion Cycle | 227 | 348 | 429 |
Working Capital Days | 183 | 269 | 384 |
ROCE % | 18% | 7% |
Documents
Announcements
-
Statement Of Deviation Or Variation In The Use Of Proceeds Of Qualified Institutions Placement (QIP)
3m - Statement confirming no deviation in QIP fund usage.
-
Announcement under Regulation 30 (LODR)-Monitoring Agency Report
7m - Submission of Monitoring Agency Report for Q3 2024.
-
Audio Recording Of The Earning Call Held On January 17, 2025
12m - Audio recording of Q3 earnings conference call.
-
Announcement under Regulation 30 (LODR)-Investor Presentation
23h - In accordance with Reg. 30 of the SEBI (LODR) Regulations, 2025, we herewith submit the investor presentation, as annexed.
-
Board Meeting Outcome for Outcome Of The Board Meeting Held On January 17, 2025
23h - Board approved unaudited financial results for Q3 FY2024.
Annual reports
Concalls
-
Jan 2025TranscriptNotesPPT
-
Oct 2024Transcript PPT REC
-
Jul 2024TranscriptPPT
-
Jul 2024Transcript PPT
-
May 2024Transcript PPT
-
May 2024TranscriptNotesPPT
-
Feb 2024Transcript PPT REC
-
Nov 2023Transcript PPT REC
-
Jul 2023Transcript PPT
-
Jun 2023Transcript PPT
-
May 2023TranscriptNotesPPT
-
Jan 2023Transcript PPT
-
Jan 2023TranscriptNotesPPT
-
Nov 2022Transcript PPT
-
Jul 2022Transcript PPT
-
Jun 2022Transcript PPT
Business Segments FY24[1]
Large Scale Manufacturing (59%) Advanced intermediates and specialty chemicals with application across the industry spectrum.
Contract Manufacturing (26%)
Manufacture under contractual supply agreements with MNCs.
CRAMS (14%)
Contract research, scale-up services, technology development, low volume high-value contract manufacturing.